title: Evidence for the development of p53 mutations after cytotoxic therapy in a neuroblastoma cell line.
abstract: p53 mutations are rare in neuroblastomas at diagnosis perhaps accounting for their initial response to therapy, but advanced neuroblastoma frequently relapses, and it is possible that p53 mutations develop later. Two neuroblastoma cell lines derived from the same patient before [SKNBE(1n)] and after [SKNBE(2c)] cytotoxic therapy were analyzed for the presence of chromosome 17 and p53 genes by fluorescent in situ hybridization, p53 mutations by DNA sequencing, and p53 function after irradiation by studying the transcription of p53-regulated genes, cell cycle arrest, and induction of apoptosis. The SKNBE(1n) cell line was wild-type for p53, had two p53 genes, two copies of chromosome arm 17p and showed functional p53 after irradiation. The SKNBE(2c) cell line derived from the same patient 5 months later at relapse had loss of an entire chromosome 17, resulting in hemizygosity for the p53 locus on 17p and a missense p53 mutation in exon 5, and p53 was not functional after irradiation. The appearance of a p53 mutation in a cell line derived from a relapsed neuroblastoma suggests that this may be a mechanism of resistance to therapy. If p53 mutations develop frequently in relapsed neuroblastoma, cytotoxic agents more sensitive to mutant p53 might be more effective at relapse.
authors.affiliation: Cancer Research Unit, The Medical School, University of Newcastle, Newcastle upon Tyne, United Kingdom. D.A.Tweddle@newcastle.ac.uk
authors.forename: D A
authors.initials: DA
authors.lastname: Tweddle
authors.forename: A J
authors.initials: AJ
authors.lastname: Malcolm
authors.forename: N
authors.initials: N
authors.lastname: Bown
authors.forename: A D
authors.initials: AD
authors.lastname: Pearson
authors.forename: J
authors.initials: J
authors.lastname: Lunec
mesh_terms: D050759:Cyclin-Dependent Kinase Inhibitor p21; D016213:Cyclins / Q000096:biosynthesis / Q000235:genetics; D004249:DNA Damage; D004273:DNA, Neoplasm / Q000187:drug effects / Q000528:radiation effects; D016158:Genes, p53 / Q000187:drug effects* / Q000502:physiology / Q000528:radiation effects*; D006801:Humans; D007621:Karyotyping; D020125:Mutation, Missense; D009447:Neuroblastoma / Q000235:genetics* / Q000473:pathology / Q000628:therapy; D009687:Nuclear Proteins; D011518:Proto-Oncogene Proteins / Q000096:biosynthesis / Q000235:genetics; D051736:Proto-Oncogene Proteins c-mdm2; D014407:Tumor Cells, Cultured / Q000187:drug effects / Q000528:radiation effects; D016159:Tumor Suppressor Protein p53 / Q000096:biosynthesis / Q000502:physiology
chemical_list: C493956:CDKN1A protein, human; D050759:Cyclin-Dependent Kinase Inhibitor p21; D016213:Cyclins; D004273:DNA, Neoplasm; D009687:Nuclear Proteins; D011518:Proto-Oncogene Proteins; D016159:Tumor Suppressor Protein p53; C497206:MDM2 protein, human; D051736:Proto-Oncogene Proteins c-mdm2